News | December 02, 2014

Heart Muscle Inflammation and Swelling Peak Twice After Heart Attack

Identification of this second wave of inflammation may advance the use of cardiac magnetic resonance (CMR) imaging to better assess initial damage caused by a heart attack

Clinical Trial at the American Heart Association (AHA) Scientific Sessions 2014

Photo courtesy of Physio-control PR photos


December 2, 2014 Results of a new study challenge the current consensus in cardiology that peak myocardial edema only occurs just after a myocardial infarction. In the study, presented as a Late-Breaking Clinical Trial at the American Heart Association (AHA) Scientific Sessions 2014 and published simultaneously in the Journal of the American College of Cardiology (JACC), scientists discovered a second wave of swelling and inflammation occurs within a week of a heart attack.

The researchers from the Mount Sinai Heart at Icahn School of Medicine at Mount Sinai and Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Spain believe their identification of this second wave of inflammation may advance the use of cardiac magnetic resonance (CMR) imaging to better assess initial damage caused by a heart attack. Furthermore, it may enable the design of future targeted therapies that interrupt the two inflammatory reactions to better protect a patient’s heart muscle.

Previously, it was widely accepted that heart muscle responds in a stable and progressive way to a heart attack or blockage, with the response pattern starting right after the attack and lasting at least a week.

“Our study found that the inflammatory reaction of the heart post-heart attack is not stable or homogeneous,” says senior study author Borja Ibáñez, M.D., Ph.D., head of the Experimental Cardiology Group at CNIC and clinical cardiologist at the Hospital Clínico San Carlos in Spain. In fact, we have identified that a new systematic and consistent two-wave inflammatory reaction occurs causing swelling and thickening of the heart muscle at two different times during a week’s time.”

The current research team first categorized this two-phase inflammatory response as an initial massive inflammatory reaction immediately after a myocardial infarction, accompanied by a massive increase in the myocardial tissue thickness that lasts a week.  Subsequent observations, however, determined that a first wave of inflammation subsides a few hours after a heart attack, and then a second, separate wave of inflammation arises a week later.

“Our study shows the first evidence of the heart’s dual inflammatory reaction after a myocardial infarction,” says study author Valentin Fuster, M.D., Ph.D., director of Mount Sinai Heart at Icahn School of Medicine at Mount Sinai and general director of CNIC in Spain. “We now know the heart responds to a myocardial infarction in a different way than we once thought with the initial inflammatory reaction followed by a second reactive inflammatory wave. This new data may be truly paradigm-shifting for the future treatment of heart attack patients.”

In the preclinical study, researchers performed comprehensive imaging using advanced 3 Tesla CMR technology to study the myocardium’s inflammatory process, and later examined heart muscle tissue samples to assess its overall water content swelling.

Myocardial Edema After Ischemia/Reperfusion is Not Stable and Follows a Bimodal Pattern: Advanced Imaging and Histological Tissue Characterization Study to Challenge a Classical Dogma.

For more information: www.mountsinai.org 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now